Clinical Trial Update: Ascorbic Acid on Restenosis of Dysfunctional Hemodialysis Vascular Access [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ascorbic acid for restenosis in dysfunctional hemodialysis vascular access has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Hemodialysis Access Dysfunction

Drugs mentioned

• Ascorbic acid (Vitamin C)

Snippet

Sponsor: National Taiwan University Hospital Hsin-Chu Branch | Conditions: Hemodialysis Access Failure | Phase 2 | Status: COMPLETED